Tonix Pharmaceuticals Completes Pharmacokinetic Study on New Formulation of TNX-102 for Fibromyalgia

Tonix Pharmaceuticals completed a pharmacokinetic study of the first formulation of its lead drug, TNX-102, for the treatment of fibromyalgia syndrome.
MarketWatch